Safety and Current Status of the COVID-19 Vaccine among Patients with Breast cancer: A Cross-Sectional Study from China
Shaohua Zhang(Wenzhou Medical University), Zefei Jiang, Ying Lin(Sun Yat-sen University), Ruonan Xu(Medical University of Graz), Hong Liu(Tianjin Medical University Cancer Institute and Hospital), Xinlan Liu(Yunnan Agricultural University), Tao Sun(Liaoning Cancer Hospital & Institute), Zhimin Fan(Nanjing University of Chinese Medicine), Yuee Teng(First Hospital of China Medical University), Jianbin Li(Academy of Military Medical Sciences), Cuizhi Geng(Hebei Medical University), Feng Jin(Hebei University), Fu‐Sheng Wang(National Clinical Research Center for Digestive Diseases), Xiaojia Wang(Ministry of Education), Jing Luo, Yali Cao(Third Hospital of Nanchang), Yiding Chen(Second Affiliated Hospital of Zhejiang University), Xinzheng Li(Shanxi Provincial Cancer Hospital), Jianyun Nie(Kunming Medical University), Gang Sun(Xinjiang Medical University), Guiying Xu(Soochow University), Qianjun Chen(Guangzhou University of Chinese Medicine), Yinhua Liu(Peking University), Man Li(Dalian Medical University), Ting Luo(Inserm)
Cited by 1
Related Papers
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
|New England Journal of Medicine|2022|2.5k
Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015
|Annals of Oncology|2015|1.8k
De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017
|Annals of Oncology|2017|1.3k